Rhabdomyosarcoma in low‐ and middle‐income countries: A report from the Asociacion de Hemato‐oncología Pediatrica de Centro América (AHOPCA)-Reference-Cited by-同舟云学术

Rhabdomyosarcoma in low‐ and middle‐income countries: A report from the Asociacion de Hemato‐oncología Pediatrica de Centro América (AHOPCA)

Published:2022-03-16 Issue: Volume: Page:
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatric Blood & Cancer

Author:

Garrido Claudia¹,Letona Tomás¹,Godoy Susana¹,Antillón Federico¹,Valverde Patricia¹,Luna‐Finemann Sandra²^ORCID,Rodríguez‐Galindo Carlos³^ORCID,Fuentes Soad⁴,Arambu Ingrid⁵,Calderón Patricia⁶,Ortiz Roberta⁶,Montero Margarita⁷,Blanco Jessica¹,Valsecchi Maria Grazia⁸,Ferrari Andrea⁹^ORCID

Affiliation:

1. National Pediatric Oncology Unit UNOP Guatemala City Guatemala

2. Hematology/Oncology/SCT Children's Hospital Colorado University of Colorado Aurora Colorado

3. Department of Global Pediatric Medicine St Jude Children's Research Hospital Memphis Tennessee

4. Pediatric Oncology Benjamin Bloom National Children's Hospital San Salvador El Salvador

5. Department of Hemato‐Oncology, Hospital Escuela Universitario UNAH Tegucigalpa Honduras

6. Department of Hemato‐Oncology Hospital Infantil Manuel de Jesus Rivera Managua Nicaragua

7. Hospital Infantil Dr. Robert Reid Cabral Santo Domingo Republica Dominicana

8. Department of Medicine and Surgery Center of Biostatistics for Clinical Epidemiology University of Milano Bicocca Monza Italy

9. Pediatric Oncology Unit Fondazione IRCCS Istituto Nazionale Tumori Milano Italy

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pbc.29669

Reference32 articles.

1. Rhabdomyosarcoma in Children: A SEER Population Based Study

2. Rhabdomyosarcoma

3. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group

4. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial

5. Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial